Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $138,614 - $151,667
340 Added 3.58%
9,827 $3.86 Billion
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $1.15 Million - $1.37 Million
-3,342 Reduced 26.05%
9,487 $3.86 Billion
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $676 - $724
2 Added 0.02%
12,829 $4.46 Billion
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $4.03 Million - $4.51 Million
12,827 New
12,827 $4.51 Billion
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $3.36 Million - $3.78 Million
-11,757 Reduced 78.08%
3,300 $953 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $3.36 Million - $3.75 Million
-12,275 Reduced 44.91%
15,057 $4.36 Billion
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $6.42 Million - $8 Million
27,332 New
27,332 $7.13 Billion
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $4.16 Million - $4.93 Million
-16,280 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $1.03 Million - $1.35 Million
4,580 Added 39.15%
16,280 $4.73 Billion
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $467,461 - $579,875
-2,340 Reduced 16.67%
11,700 $2.78 Million
Q4 2019

Feb 10, 2020

BUY
$166.71 - $223.91 $2.34 Million - $3.14 Million
14,040 New
14,040 $3.07 Million
Q2 2019

Aug 13, 2019

SELL
$164.61 - $190.37 $872,433 - $1.01 Million
-5,300 Closed
0 $0
Q1 2019

Apr 18, 2019

BUY
$163.73 - $194.7 $867,769 - $1.03 Million
5,300 New
5,300 $975,000
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $14.3 Million - $16.7 Million
-98,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $14.9 Million - $17.4 Million
98,000 New
98,000 $16 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Barometer Capital Management Inc. Portfolio

Follow Barometer Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barometer Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Barometer Capital Management Inc. with notifications on news.